Daichirona (monovalent, Original)

Initial Approval

Coronavirus (SARS-CoV-2) RNA Vaccine (active ingredient: ufrenmeran)

Approval Information

Brand NameDaichirona (monovalent, Original)

Generic NameCoronavirus (SARS-CoV-2) RNA Vaccine (active ingredient: ufrenmeran)

ApprovedAugust 2023

TypeInitial Approval

Review Reports

English Review Report

PDF · 1.89 MB

Japanese Review Report

PDF · 1.73 MB

Want structured data, translation summaries & alerts?

PharmaLens is building the most comprehensive English-language PMDA intelligence platform. Join the waitlist for early access.

Join the Waitlist

Source: PMDA Website. Review reports are provided under Japan's Public Data License v1.0. Translations and structured data by PharmaLens are unofficial and for reference only.

← Back to Drug Database